Details of the Drug

General Information of Drug (ID: DMF6Z5T)

Drug Name
Glecaprevir; pibrentasvir
Synonyms pibrentasvir; Maviret; Mavyret; Glecaprevir / pibrentasvir; Glecaprevir and pibrentasvir; ABT-493/ABT-530; Glecaprevir mixture with pibrentasvir; ABT-493 / ABT-530; S900007520
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Approved [1]
Drug Type
Combination drug
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 110 mcg/L []
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h []
Elimination
96.6% of administered drug is excreted in feces []
Half-life
The concentration or amount of drug in body reduced by one-half in 13 hours []
Metabolism
The drug is not metabolised []
Cross-matching ID
PubChem CID
66828839; 58031952
TTD ID
D0C4DH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus Non-structural 5A (HCV NS5A) TTCJ2X8 POLG_HCV1 Inhibitor [1]
Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) TTHC7JD POLG_HCV1 Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.